drugset / Trial / NCT06281327
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
Phase 2
Recruiting
60 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Henan Cancer Hospital · collabThe Second Affiliated Hospital of Kunming Medical University · collabTianjin Children's Hospital · collabTianjin Medical University Second Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of avatrombopag in the treatment of pediatric primary immune thrombocytopenia in patients who have been treated with eltrombopag before and switched to avatrobopag because of poor efficacy, excessive platelet fluctuation or intolerance, or patient preference, economic reasons, and other reasons.
Timeline
- Start
- 2024-03-01
- Primary completion
- 2025-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avatrombopag | Small molecule | 10 mg | Oral |
| Subject | Avatrombopag | Small molecule | 20 mg | Oral |
| Subject | Avatrombopag | Small molecule | 40 mg | Oral |